Skip to content

The safety and efficacy of intra-articular and peri-articular injection in total knee arthroplasty

The safety and efficacy of intra-articular and peri-articular injection in total knee arthroplasty

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-16010099
Enrollment
Unknown
Registered
2016-12-07
Start date
2016-12-31
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee end-stage diseases

Interventions

1:Intra-articular injection analgesia
2:peri-articular injection analgesia
3:Intra-articular injection combines peri-articular injection analgesia

Sponsors

Chinese Academy of Medical Sciences, Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Aged >18 years male or female patients; 2. Diagonosis with OA or RA; 3. Plan to receive unilateral total knee replacement.

Exclusion criteria

Exclusion criteria: 1. Patients with a history of allergy to any of the injectable drug ingredients or excipients; 2. Active gastrointestinal ulcers or gastrointestinal bleeding; 3. Patients with bronchospasm, acute rhinitis, nasal polyps, angioneurotic edema, urticaria, and other allergic reactions after taking aspirin or nonsteroidal anti-inflammatory drugs (including COX-2 inhibitors); 4. Knee severe varus or valgus deformity; 5. Severe liver injury (serum albumin <25g / L or Child-Pugh score =10); 6. Inflammatory bowel disease; 7. Congestive heart failure (NYHAII-IV); 8. Opioids abuse 9. Peripheral arterial and / or cerebrovascular diseases.

Design outcomes

Secondary

MeasureTime frame
Visual analogue scale at rest;Visual analogue scale in activity;knee range of motion;postoperative days required to stand;postoperative days required to straight leg elevation;complications;other safety indexes;

Primary

MeasureTime frame
Consumption of opioids;

Countries

China

Contacts

Public ContactWENG Xisheng

Chinese Academy of Medical Sciences, Peking Union Medical College Hospital

wengxisheng@126.com+86 13366200018

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026